While the use of visual methods in qualitative research is gaining recognition, there has been less attention to timelines. This paper addresses this gap and contributes to the overall literature on qualitative research design and analysis. In a randomized trial of extended release naltrexone for youth with opioid use disorder timelines were used as a part of the semi-structured interview process. Timelines were constructed in a participatory manner in which both youth and their caregivers were separately asked to recount significant events related to substance use, treatment, and criminal justice involvement that took place between interview time points. This paper suggests that using timelines in qualitative, substance use research offers two main advantages: 1) improving the data collection process, and 2) advancing understandings of temporally contextualized narratives through a visual format. Here, timelines were an integral tool for summarizing and illustrating the complexity of youths’ experiences following residential drug treatment.
To characterize injuries occurring in jails, we analyzed injury report forms from the New York City jail system. We abstracted data from 4695 injury report forms representing 3863 patients. Of the injuries reported, 66% were classified as intentional. The 2 leading causes of injuries were inmate-on-inmate aggression (40%) and slips and falls (27%). Injuries place a considerable burden on jail health care systems, and there is a need for more studies on this problem and development of injury prevention programs.
Background and Aims
Opioid overdose deaths among adolescents and young adults have risen sharply in the United States over recent decades. This study aimed to explore the nature of adolescent and young adult perspectives on overdose experiences.
Design
This study involved thematic analysis of interviews undertaken as part of a mixed‐methods, randomized trial of extended release naltrexone (XR‐NTX) versus treatment‐as‐usual (TAU) for adolescents and young adults (aged 15–21 years) with opioid use disorder (OUD).
Setting
Participants were recruited during a residential treatment episode at Mountain Manor Treatment Center, in Baltimore, MD, USA.
Participants/cases
As part of the qualitative component of this study, 35 adolescents/young adults completed up to three interviews: at baseline, 3 and 6 months after release from residential opioid use disorder treatment.
Measurements
Semi‐structured interviews solicited participant experiences with opioid use disorder treatment; their satisfaction with the medications used to treat opioid use disorder; counseling received; current substance use; issues related to treatment retention; their treatment goals; and their future outlook.
Findings
Four broad themes emerged: (1) adolescents/young adults had difficulty identifying overdoses due to interpreting subjective symptoms and a lack of memory of the event, (2) this sample had difficulty perceiving risk that is misaligned with traditional understandings of overdose intentionality, (3) adolescents/young adults did not interpret personal overdose events as a catalyst for behavior change and (4) this sample experienced a greater impact to behavior change through witnessing an overdose of someone in their social network.
Conclusions
The sample of US adolescents and young adults in treatment for opioid use disorder expressed difficulty identifying whether or not they had experienced an overdose, expressed fluctuating intentionality for those events and did not have clear intentions to change their behavior. Witnessing an overdose appeared to be as salient an experience as going through an overdose oneself.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.